You can buy or sell PTLA and other stocks, options, ETFs, and crypto commission-free!
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. It offers Andexxa, and Bevyxxa medicines. Read More The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
The Motley FoolMar 1
Why Portola Pharmaceuticals Skyrocketed 15.3% Today
What happened After it reported fourth-quarter results and solidified its cash position without issuing more shares, Portola Pharmaceuticals (NASDAQ:PTLA) shares had gained 15.3% at noon EST on Friday. So what Portola Pharmaceuticals has struggled in its bid to go from promising clinical-stage upstart to commercial-stage darling. Despite Food and Drug Administration (FDA) approval for two distinct therapies, lackluster sales have dampened investors' enthusiasm. In its fourth-quarter earnings report, the...
Seeking AlphaMar 1
Portola Pharmaceuticals beats by $0.07, beats on revenue
Portola Pharmaceuticals (NASDAQ:PTLA): Q4 Non-GAAP EPS of -$1.04 beats by $0.07; GAAP EPS of -$1.34 misses by $0.23. Revenue of $15.3M (+56.1% Y/Y) beats by $4.35M . Shares +4.36% PM. Press Release...
Seeking AlphaFeb 28
Portola Pharmaceuticals Q4 Earnings Preview
Portola Pharmaceuticals (NASDAQ:PTLA) is scheduled to announce Q4 earnings results on Friday, March 1st, before market open. The consensus EPS Estimate is -$1.11 (+21.3% Y/Y) and the consensus Revenue Estimate is $10.95M (+11.7% Y/Y). Over the last 2 years, PTLA has beaten EPS estimates 63% of the time and has beaten revenue estimates 50% of the time....
Expected May 8, Pre-Market